Imaging Probes for Precision Medicine in Alzheimer's Disease
Here I aim to develop and refine [18F]-labeled imaging tools to guide the clinical development of a new class of drugs with disease-modifying potential, the epichaperome targeting agents.
Detailed Non-Technical Summary
Finding an appropriate treatment regimen is the goal of personalized precision medicine. I aim to develop and refine imaging tools that can be used to develop a new experimental treatment strategy with disease-modifying potential. This therapeutic, PU-AD, works by rebalancing damaged cellular networks and brain circuits. In mouse models, PU-AD treatment reversed cognitive dysfunction and is currently undergoing clinical evaluation in AD and related disorders. Therefore, the imaging tools that I am developing and bringing to the clinic may have immediate, transformative translational potential.
The [18F]-labeled epichaperome probe could serve as a companion diagnostic to the therapeutic PU-AD or other emerging epichaperome therapies. The probe will complement this therapeutic platform - consisting of drug candidate, biomarker and diagnostic – with our ultimate goal being precision medicine for AD and ADRD. In addition, imaging epichaperomes may have clear diagnostic implications as the spatial distribution of brain network dysfunction via epichaperome imaging, could offer valuable information for tracking and staging within individuals and groups across the AD spectrum. Application of imaging in human studies offers unique opportunities to understand pathophysiology and treatment. The epichaperome imaging probe may aid in determining the interaction of PU-AD with its target, in guiding initial dosing of epichaperome therapeutic agents, and in identifying patients most likely to benefit from epichaperome therapy. Importantly, this probe could be added to the currently available imaging biomarker portfolio for AD to capture the anticipated spatiotemporal progression of the disease from very early stage, facilitating early clinical intervention.
First published on: August 18, 2022
Last modified on: March 21, 2023